TY - JOUR AU - Torre, L. AU - Bray, F. AU - Siegel, R. AU - Ferlay, J. AU - Lortet-Tieulent, J. AU - Jemal, A. PY - 2015 DA - 2015// TI - Global cancer statistics, 2012 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21262 DO - 10.3322/caac.21262 ID - Torre2015 ER - TY - JOUR AU - Bruix, J. AU - Sherman, M. PY - 2011 DA - 2011// TI - American Association for the Study of liver D. Management of hepatocellular carcinoma: an update JO - Hepatology VL - 53 UR - https://doi.org/10.1002/hep.24199 DO - 10.1002/hep.24199 ID - Bruix2011 ER - TY - JOUR AU - Llovet, J. AU - Bru, C. AU - Bruix, J. PY - 1999 DA - 1999// TI - Prognosis of hepatocellular carcinoma: the BCLC staging classification JO - Semin Liver Dis VL - 19 UR - https://doi.org/10.1055/s-2007-1007122 DO - 10.1055/s-2007-1007122 ID - Llovet1999 ER - TY - JOUR AU - Cheng, A. AU - Kang, Y. AU - Chen, Z. AU - Tsao, C. AU - Qin, S. AU - Kim, J. AU - Luo, R. AU - Feng, J. AU - Ye, S. AU - Yang, T. PY - 2009 DA - 2009// TI - Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial JO - Lancet Oncol VL - 10 UR - https://doi.org/10.1016/S1470-2045(08)70285-7 DO - 10.1016/S1470-2045(08)70285-7 ID - Cheng2009 ER - TY - JOUR AU - Llovet, J. AU - Ricci, S. AU - Mazzaferro, V. AU - Hilgard, P. AU - Gane, E. AU - Blanc, J. AU - de Oliveira, A. AU - Santoro, A. AU - Raoul, J. AU - Forner, A. PY - 2008 DA - 2008// TI - Sorafenib in advanced hepatocellular carcinoma JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708857 DO - 10.1056/NEJMoa0708857 ID - Llovet2008 ER - TY - JOUR AU - Nishikawa, H. AU - Osaki, Y. AU - Endo, M. AU - Takeda, H. AU - Tsuchiya, K. AU - Joko, K. AU - Ogawa, C. AU - Taniguchi, H. AU - Orito, E. AU - Uchida, Y. PY - 2014 DA - 2014// TI - Comparison of standard-dose and half dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: a propensity score matching analysis JO - Int J Oncol VL - 45 UR - https://doi.org/10.3892/ijo.2014.2654 DO - 10.3892/ijo.2014.2654 ID - Nishikawa2014 ER - TY - JOUR AU - Morimoto, M. AU - Numata, K. AU - Kondo, M. AU - Kobayashi, S. AU - Ohkawa, S. AU - Hidaka, H. AU - Nakazawa, T. AU - Okuwaki, Y. AU - Okuse, C. AU - Matsunaga, K. PY - 2015 DA - 2015// TI - Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: a propensity score analysis JO - Hepatol Res VL - 45 UR - https://doi.org/10.1111/hepr.12354 DO - 10.1111/hepr.12354 ID - Morimoto2015 ER - TY - JOUR AU - Iavarone, M. AU - Cabibbo, G. AU - Piscaglia, F. AU - Zavaglia, C. AU - Grieco, A. AU - Villa, E. AU - Camma, C. AU - Colombo, M. PY - 2011 DA - 2011// TI - Group Ss. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy JO - Hepatology VL - 54 UR - https://doi.org/10.1002/hep.24644 DO - 10.1002/hep.24644 ID - Iavarone2011 ER - TY - JOUR AU - Bruix, J. AU - Reig, M. AU - Sherman, M. PY - 2016 DA - 2016// TI - Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma JO - Gastroenterology VL - 150 UR - https://doi.org/10.1053/j.gastro.2015.12.041 DO - 10.1053/j.gastro.2015.12.041 ID - Bruix2016 ER - TY - JOUR AU - Uka, K. AU - Aikata, H. AU - Takaki, S. AU - Shirakawa, H. AU - Jeong, S. AU - Yamashina, K. AU - Hiramatsu, A. AU - Kodama, H. AU - Takahashi, S. AU - Chayama, K. PY - 2007 DA - 2007// TI - Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma JO - World J Gastroenterol VL - 13 UR - https://doi.org/10.3748/wjg.v13.i3.414 DO - 10.3748/wjg.v13.i3.414 ID - Uka2007 ER - TY - JOUR AU - Okusaka, T. AU - Okada, S. AU - Ishii, H. AU - Nose, H. AU - Nagahama, H. AU - Nakasuka, H. AU - Ikeda, K. AU - Yoshimori, M. PY - 1997 DA - 1997// TI - Prognosis of hepatocellular carcinoma patients with extrahepatic metastases JO - Hepato-Gastroenterology VL - 44 ID - Okusaka1997 ER - TY - JOUR AU - Yoo, D. AU - Kim, K. AU - Jin, Y. AU - Shim, J. AU - Ko, G. AU - Yoon, H. AU - Sung, K. AU - Lee, J. AU - Kang, Y. AU - Lim, Y. PY - 2011 DA - 2011// TI - Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? JO - J Gastroen Hepatol. VL - 26 UR - https://doi.org/10.1111/j.1440-1746.2010.06341.x DO - 10.1111/j.1440-1746.2010.06341.x ID - Yoo2011 ER - TY - JOUR AU - Bruix, J. AU - Llovet, J. AU - Castells, A. AU - Montana, X. AU - Bru, C. AU - Ayuso, M. AU - Vilana, R. AU - Rodes, J. PY - 1998 DA - 1998// TI - Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution JO - Hepatology VL - 27 UR - https://doi.org/10.1002/hep.510270617 DO - 10.1002/hep.510270617 ID - Bruix1998 ER - TY - JOUR AU - Nishikawa, H. AU - Osaki, Y. AU - Iguchi, E. AU - Takeda, H. AU - Nakajima, J. AU - Matsuda, F. AU - Sakamoto, A. AU - Henmi, S. AU - Hatamaru, K. AU - Saito, S. PY - 2012 DA - 2012// TI - Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma JO - Exp Ther Med VL - 4 UR - https://doi.org/10.3892/etm.2012.611 DO - 10.3892/etm.2012.611 ID - Nishikawa2012 ER - TY - JOUR AU - Pinter, M. AU - Hucke, F. AU - Graziadei, I. AU - Vogel, W. AU - Maieron, A. AU - Konigsberg, R. AU - Stauber, R. AU - Grunberger, B. AU - Muller, C. AU - Kolblinger, C. PY - 2012 DA - 2012// TI - Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib JO - Radiology VL - 263 UR - https://doi.org/10.1148/radiol.12111550 DO - 10.1148/radiol.12111550 ID - Pinter2012 ER - TY - JOUR AU - Chern, M. AU - Chuang, V. AU - Liang, C. AU - Lin, Z. AU - Kuo, T. PY - 2014 DA - 2014// TI - Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors JO - J Vasc Interv Radiol VL - 25 UR - https://doi.org/10.1016/j.jvir.2013.10.013 DO - 10.1016/j.jvir.2013.10.013 ID - Chern2014 ER - TY - JOUR AU - Chung, G. AU - Lee, J. AU - Kim, H. AU - Hwang, S. AU - Kim, J. AU - Chung, J. AU - Yoon, J. AU - Lee, H. AU - Kim, Y. PY - 2011 DA - 2011// TI - Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival JO - Radiology VL - 258 UR - https://doi.org/10.1148/radiol.10101058 DO - 10.1148/radiol.10101058 ID - Chung2011 ER - TY - JOUR AU - Georgiades, C. AU - Hong, K. AU - D'Angelo, M. AU - Geschwind, J. PY - 2005 DA - 2005// TI - Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis JO - J Vasc Interv Radiol VL - 16 UR - https://doi.org/10.1097/01.RVI.0000182185.47500.7A DO - 10.1097/01.RVI.0000182185.47500.7A ID - Georgiades2005 ER - TY - JOUR AU - Luo, J. AU - Guo, R. AU - Lai, E. AU - Zhang, Y. AU - Lau, W. AU - Chen, M. AU - Shi, M. PY - 2011 DA - 2011// TI - Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study JO - Ann Surg Oncol VL - 18 UR - https://doi.org/10.1245/s10434-010-1321-8 DO - 10.1245/s10434-010-1321-8 ID - Luo2011 ER - TY - JOUR AU - Kim, K. AU - Kim, J. AU - Park, I. AU - Ko, G. AU - Yoon, H. AU - Sung, K. AU - Lim, Y. AU - Lee, H. AU - Chung, Y. AU - Lee, Y. PY - 2009 DA - 2009// TI - Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion JO - J Gastroen Hepatol VL - 24 UR - https://doi.org/10.1111/j.1440-1746.2008.05728.x DO - 10.1111/j.1440-1746.2008.05728.x ID - Kim2009 ER - TY - JOUR AU - Lee, H. AU - Kim, J. AU - Choi, I. AU - Chung, J. AU - Park, J. AU - Kim, C. PY - 1997 DA - 1997// TI - The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study JO - Cancer VL - 79 UR - https://doi.org/3.0.CO;2-M DO - 3.0.CO;2-M ID - Lee1997 ER - TY - JOUR AU - Kim, G. AU - Shim, J. AU - Yoon, S. AU - Jung, J. AU - Kim, J. AU - Ryu, M. AU - Ryoo, B. AU - Kang, Y. AU - Lee, D. AU - Kim, K. PY - 2015 DA - 2015// TI - Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis JO - J Vasc Interv Radiol VL - 26 UR - https://doi.org/10.1016/j.jvir.2014.10.019 DO - 10.1016/j.jvir.2014.10.019 ID - Kim2015 ER - TY - JOUR AU - Kim, H. AU - Park, J. AU - Nam, B. AU - Kim, H. AU - Choi, J. AU - Kim, T. AU - Kim, H. AU - Kim, C. PY - 2011 DA - 2011// TI - Survival of patients with advanced hepatocellular carcinoma: Sorafenib versus other treatments JO - J Gastroen Hepatol. VL - 26 UR - https://doi.org/10.1111/j.1440-1746.2011.06751.x DO - 10.1111/j.1440-1746.2011.06751.x ID - Kim2011 ER - TY - JOUR AU - Briggs, A. AU - Sculpher, M. PY - 1998 DA - 1998// TI - An introduction to Markov modelling for economic evaluation JO - PharmacoEconomics VL - 13 UR - https://doi.org/10.2165/00019053-199813040-00003 DO - 10.2165/00019053-199813040-00003 ID - Briggs1998 ER - TY - JOUR AU - Parsonnet, J. AU - Harris, R. AU - Hack, H. AU - Owens, D. PY - 1996 DA - 1996// TI - Modelling cost-effectiveness of helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials JO - Lancet VL - 348 UR - https://doi.org/10.1016/S0140-6736(96)01501-2 DO - 10.1016/S0140-6736(96)01501-2 ID - Parsonnet1996 ER - TY - JOUR AU - Nayagam, S. AU - Conteh, L. AU - Sicuri, E. AU - Shimakawa, Y. AU - Suso, P. AU - Tamba, S. AU - Njie, R. AU - Njai, H. AU - Lemoine, M. AU - Hallett, T. PY - 2016 DA - 2016// TI - Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in the Gambia: an economic modelling analysis JO - Lancet Glob Health VL - 4 UR - https://doi.org/10.1016/S2214-109X(16)30101-2 DO - 10.1016/S2214-109X(16)30101-2 ID - Nayagam2016 ER - TY - JOUR AU - Hillner, B. AU - Efficacy, S. T. PY - 1991 DA - 1991// TI - Cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model JO - N Engl J Med VL - 324 UR - https://doi.org/10.1056/NEJM199101173240305 DO - 10.1056/NEJM199101173240305 ID - Hillner1991 ER - TY - JOUR AU - Bell, B. AU - Manos, M. AU - Zaman, A. AU - Terrault, N. AU - Thomas, A. AU - Navarro, V. AU - Dhotre, K. AU - Murphy, R. AU - Van Ness, G. AU - Stabach, N. PY - 2008 DA - 2008// TI - The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance JO - Am J Gastroenterol VL - 103 UR - https://doi.org/10.1111/j.1572-0241.2008.02071.x DO - 10.1111/j.1572-0241.2008.02071.x ID - Bell2008 ER - TY - JOUR AU - Forner, A. AU - Llovet, J. AU - Bruix, J. PY - 2012 DA - 2012// TI - Hepatocellular carcinoma JO - Lancet VL - 379 UR - https://doi.org/10.1016/S0140-6736(11)61347-0 DO - 10.1016/S0140-6736(11)61347-0 ID - Forner2012 ER - TY - JOUR AU - Lencioni, R. AU - Llovet, J. AU - Modified, R. PY - 2010 DA - 2010// TI - (mRECIST) assessment for hepatocellular carcinoma JO - Semin Liver Dis VL - 30 UR - https://doi.org/10.1055/s-0030-1247132 DO - 10.1055/s-0030-1247132 ID - Lencioni2010 ER - TY - JOUR AU - Gomez, E. AU - Rodriguez, Y. AU - Bertot, L. AU - Gonzalez, A. AU - Perez, Y. AU - Soler, E. AU - Garcia, A. AU - Blanco, L. PY - 2013 DA - 2013// TI - The natural history of compensated HCV-related cirrhosis: a prospective long-term study JO - J Hepatol VL - 58 UR - https://doi.org/10.1016/j.jhep.2012.10.023 DO - 10.1016/j.jhep.2012.10.023 ID - Gomez2013 ER - TY - JOUR AU - Beck, J. AU - Kassirer, J. AU - Pauker, S. PY - 1982 DA - 1982// TI - A convenient approximation of life expectancy (the “DEALE”). I. Validation of the method JO - Am J Med VL - 73 UR - https://doi.org/10.1016/0002-9343(82)90786-0 DO - 10.1016/0002-9343(82)90786-0 ID - Beck1982 ER - TY - STD TI - Freeman MF, Turkey JW. Transformations related to the angular and the square root. Ann Math Stats. 1950;21:607–11. ID - ref33 ER - TY - JOUR AU - Newcombe, R. PY - 1998 DA - 1998// TI - Two-sided confidence intervals for the single proportion: comparison of seven methods JO - Stat Med VL - 17 UR - https://doi.org/3.0.CO;2-E DO - 3.0.CO;2-E ID - Newcombe1998 ER - TY - STD TI - Department Of Health And Human Services NCFH, Statistics. National Vital Statistics Reports 2006;57(14). Available at: www.dhhs.gov. (Accessed on April 17, 2009). UR - http://www.dhhs.gov ID - ref35 ER - TY - JOUR AU - Cabibbo, G. AU - Maida, M. AU - Genco, C. AU - Parisi, P. AU - Peralta, M. AU - Antonucci, M. AU - Brancatelli, G. AU - Camma, C. AU - Craxi, A. AU - Di Marco, V. PY - 2012 DA - 2012// TI - Natural history of untreatable hepatocellular carcinoma: a retrospective cohort study JO - World J Hepatol VL - 4 UR - https://doi.org/10.4254/wjh.v4.i9.256 DO - 10.4254/wjh.v4.i9.256 ID - Cabibbo2012 ER - TY - JOUR AU - Giannini, E. AU - Farinati, F. AU - Ciccarese, F. AU - Pecorelli, A. AU - Rapaccini, G. AU - Di Marco, M. AU - Benvegnu, L. AU - Caturelli, E. AU - Zoli, M. AU - Borzio, F. PY - 2015 DA - 2015// TI - Prognosis of untreated hepatocellular carcinoma JO - Hepatology VL - 61 UR - https://doi.org/10.1002/hep.27443 DO - 10.1002/hep.27443 ID - Giannini2015 ER - TY - JOUR AU - Liu, L. AU - Zhang, C. AU - Zhao, Y. AU - Qi, X. AU - Chen, H. AU - Bai, W. AU - He, C. AU - Guo, W. AU - Yin, Z. AU - Fan, D. PY - 2014 DA - 2014// TI - Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients JO - Biomed Res Int VL - 2014 ID - Liu2014 ER - TY - JOUR AU - Hu, H. AU - Duan, Z. AU - Long, X. AU - Hertzanu, Y. AU - Shi, H. AU - Liu, S. AU - Yang, Z. PY - 2014 DA - 2014// TI - Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0096620 DO - 10.1371/journal.pone.0096620 ID - Hu2014 ER - TY - JOUR AU - Zhou, B. AU - Yan, Z. AU - Liu, R. AU - Shi, P. AU - Qian, S. AU - Qu, X. AU - Zhu, L. AU - Zhang, W. AU - Wang, J. PY - 2016 DA - 2016// TI - Prospective study of transcatheter arterial chemoembolization (TACE) with ginsenoside Rg3 versus TACE alone for the treatment of patients with advanced hepatocellular carcinoma JO - Radiology VL - 280 UR - https://doi.org/10.1148/radiol.2016150719 DO - 10.1148/radiol.2016150719 ID - Zhou2016 ER - TY - JOUR AU - Llovet, J. AU - Bustamante, J. AU - Castells, A. AU - Vilana, R. AU - Ayuso Mdel, C. AU - Sala, M. AU - Bru, C. AU - Rodes, J. AU - Bruix, J. PY - 1999 DA - 1999// TI - Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials JO - Hepatology VL - 29 UR - https://doi.org/10.1002/hep.510290145 DO - 10.1002/hep.510290145 ID - Llovet1999 ER - TY - JOUR AU - Bruix, J. AU - Raoul, J. AU - Sherman, M. AU - Mazzaferro, V. AU - Bolondi, L. AU - Craxi, A. AU - Galle, P. AU - Santoro, A. AU - Beaugrand, M. AU - Sangiovanni, A. PY - 2012 DA - 2012// TI - Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial JO - J Hepatol VL - 57 UR - https://doi.org/10.1016/j.jhep.2012.06.014 DO - 10.1016/j.jhep.2012.06.014 ID - Bruix2012 ER - TY - JOUR AU - Abou-Alfa, G. AU - Schwartz, L. AU - Ricci, S. AU - Amadori, D. AU - Santoro, A. AU - Figer, A. AU - De Greve, J. AU - Douillard, J. AU - Lathia, C. AU - Schwartz, B. PY - 2006 DA - 2006// TI - Phase II study of sorafenib in patients with advanced hepatocellular carcinoma JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.01.3441 DO - 10.1200/JCO.2005.01.3441 ID - Abou-Alfa2006 ER - TY - JOUR AU - Cheng, A. AU - Guan, Z. AU - Chen, Z. AU - Tsao, C. AU - Qin, S. AU - Kim, J. AU - Yang, T. AU - Tak, W. AU - Pan, H. AU - Yu, S. PY - 2012 DA - 2012// TI - Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/j.ejca.2011.12.006 DO - 10.1016/j.ejca.2011.12.006 ID - Cheng2012 ER - TY - JOUR AU - Cho, J. AU - Paik, Y. AU - Park, H. AU - Yu, J. AU - Sohn, W. AU - Gwak, G. AU - Choi, M. AU - Lee, J. AU - Koh, K. AU - Paik, S. PY - 2014 DA - 2014// TI - The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma JO - Liver Int VL - 34 UR - https://doi.org/10.1111/liv.12445 DO - 10.1111/liv.12445 ID - Cho2014 ER - TY - STD TI - Iavarone M, Cabibbo G, Biolato M, Della Corte C, Maida M, Barbara M, Basso M, Vavassori S, Craxi A, Grieco A, et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology. 2015;62(3):784–91. ID - ref46 ER - TY - STD TI - Lee I, Chen Y, Chao Y, Huo T, Li C, Su C, Lin H, Lee F, Huang Y. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore). 2015;94(14):e688. ID - ref47 ER - TY - JOUR AU - Zhang, P. AU - Yang, Y. AU - Wen, F. AU - He, X. AU - Tang, R. AU - Du, Z. AU - Zhou, J. AU - Zhang, J. AU - Li, Q. PY - 2015 DA - 2015// TI - Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma JO - Eur J Gastroen Hepat VL - 27 UR - https://doi.org/10.1097/MEG.0000000000000373 DO - 10.1097/MEG.0000000000000373 ID - Zhang2015 ER - TY - JOUR AU - Lim, K. AU - Wang, V. AU - Siddiqui, F. AU - Shi, L. AU - Chan, E. AU - Oh, H. AU - Tan, S. AU - Chow, P. PY - 2015 DA - 2015// TI - Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria JO - Hepatology VL - 61 UR - https://doi.org/10.1002/hep.27135 DO - 10.1002/hep.27135 ID - Lim2015 ER - TY - JOUR AU - Carr, B. AU - Carroll, S. AU - Muszbek, N. AU - Gondek, K. PY - 2010 DA - 2010// TI - Economic evaluation of sorafenib in unresectable hepatocellular carcinoma JO - J Gastroenterol Hepatol VL - 25 UR - https://doi.org/10.1111/j.1440-1746.2010.06404.x DO - 10.1111/j.1440-1746.2010.06404.x ID - Carr2010 ER - TY - JOUR AU - Pollom, E. AU - Lee, K. AU - Durkee, B. PY - 2017 DA - 2017// TI - Cost-effectiveness of stereotactic body radiation therapy versus radiofrequency ablation for hepatocellular carcinoma: a Markov modeling study JO - Radiology VL - 283 UR - https://doi.org/10.1148/radiol.2016161509 DO - 10.1148/radiol.2016161509 ID - Pollom2017 ER - TY - STD TI - NICE technology appraisal guidance 189 — Sorafenib for the treatment of advanced hepatocellular carcinoma www.nice.org.uk/guidance/TA189. UR - http://www.nice.org.uk/guidance/TA189 ID - ref52 ER - TY - JOUR AU - Cucchetti, A. AU - Piscaglia, F. AU - Cescon, M. PY - 2013 DA - 2013// TI - Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma JO - J Hepatol VL - 59 UR - https://doi.org/10.1016/j.jhep.2013.04.009 DO - 10.1016/j.jhep.2013.04.009 ID - Cucchetti2013 ER - TY - BOOK AU - Neumann, P. AU - Ganiats, T. AU - Russell, L. AU - Sanders, G. AU - Siegel, J. PY - 2016 DA - 2016// TI - Cost-effectiveness in health and medicine PB - OUP CY - USA UR - https://doi.org/10.1093/acprof:oso/9780190492939.001.0001 DO - 10.1093/acprof:oso/9780190492939.001.0001 ID - Neumann2016 ER - TY - JOUR AU - Camma, C. AU - Cabibbo, G. AU - Petta, S. AU - Enea, M. AU - Iavarone, M. AU - Grieco, A. AU - Gasbarrini, A. AU - Villa, E. AU - Zavaglia, C. AU - Bruno, R. PY - 2013 DA - 2013// TI - Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma JO - Hepatology VL - 57 UR - https://doi.org/10.1002/hep.26221 DO - 10.1002/hep.26221 ID - Camma2013 ER - TY - JOUR AU - Grosse, S. PY - 2008 DA - 2008// TI - Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold JO - Expert Rev Pharmacoecon Outcomes Res VL - 8 UR - https://doi.org/10.1586/14737167.8.2.165 DO - 10.1586/14737167.8.2.165 ID - Grosse2008 ER - TY - JOUR AU - Murray, C. AU - Evans, D. AU - Acharya, A. AU - Baltussen, R. PY - 2000 DA - 2000// TI - Development of WHO guidelines on generalized cost-effectiveness analysis JO - Health Econ VL - 9 UR - https://doi.org/3.0.CO;2-O DO - 3.0.CO;2-O ID - Murray2000 ER - TY - JOUR AU - Muszbek, N. AU - Shah, S. AU - Carroll, S. AU - Mcdonald, H. AU - Dale, P. AU - Maroun, J. AU - Knox, J. PY - 2008 DA - 2008// TI - Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada JO - Curr Med Res Opin VL - 24 UR - https://doi.org/10.1185/03007990802563706 DO - 10.1185/03007990802563706 ID - Muszbek2008 ER -